Approximately a year after the FDA rejected its previous approval submission, Abeona announced that the agency had approved ZEVASKYN, its autologous cell-based gene therapy for both adult and pediatric patients with RDEB. This approval marks Abeona's entry into the commercial gene therapy...
Hence then, the article about zevaskyn approval positions abeona as emerging player in dystrophic epidermolysis bullosa market delveinsight was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market .. DelveInsight )
Also on site :
- You're Probably Wasting $200 a Month on These Sneaky Bills
- Lucid Motors’ new CEO cuts 18% of staff to ‘simplify the company’
- Olivia Rodrigo Charts All 13 Songs From ‘You Seem Pretty Sad for a Girl So in Love’ in Hot 100’s Top 30